Hydroxypropyl betadex - Mitsubishi Tanabe Pharma CorporationAlternative Names: 2-hydroxypropyl betadex - Mitsubishi Tanabe Pharma Corporation; Beta hydroxypropylcyclodextrin - Mitsubishi Tanabe Pharma Corporation; HPBCD - Mitsubishi Tanabe Pharma Corporation; Hydroxypropyl beta cyclodextrin - Mitsubishi Tanabe Pharma Corporation
Latest Information Update: 16 Dec 2015
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Beta-Cyclodextrins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Niemann-Pick diseases